Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamine amidotransferase class 1 domain containing 1 (GATD1) is a protein-coding gene and a member of the peptidase C56 family. It is a component of the FERRY complex, a five-subunit endosomal Rab5 and RNA/ribosome intermediary complex, which interacts directly with mRNAs and RAB5A. This protein is involved in facilitating the localization and distribution of specific mRNAs, most likely by mediating their endosomal transport. GATD1 is predicted to possess glyoxalase III activity, catalyzing methylglyoxal metabolism to D-lactate via S-lactoyl-glutathione, and appears to function in cellular mRNA and ribosome recruitment to early endosomes through direct mRNA interaction. There are no current reports of direct disease association, therapeutic targeting, or pharmacological modulation of GATD1 in the literature[4][1].
Not applicable; no drugs known to target this molecule
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamine amidotransferase class 1 domain containing 1 (GATD1).